Tolebrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor. This page compares Tolebrutinib with Teriflunomide (Aubagio), Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta), Ublituximab (Briumvi), and Remibrutinib (Rhapsido). These agents represent diverse approaches to disease modification, including different mechanisms of action and dosing frequencies.
Tolebrutinib Alternatives: How It Compares to Other BTK Inhibitors
Hipa.ai Research · Source: ClinicalTrials.gov / AACT · Last updated: AI-augmented data · 0/8 curated
Source: ClinicalTrials.gov via AACT · Hipa.ai, 2026-05-07Download chart as PNG
Approved comparators like Ofatumumab (Kesimpta, approved 2009) and Teriflunomide (Aubagio, approved 2012) preceded Tolebrutinib, which was not approved. Several pipeline drugs, including Evobrutinib, Fenebrutinib, and Remibrutinib, are currently in Phase 3, trailing the latest approved therapies by approximately 1-2 years.
Quick comparison table
| Drug | Class | Approved indications | Dosing | Year approved | Lead pivotal endpoint | Annual cost (rough) |
|---|---|---|---|---|---|---|
| Tolebrutinib (Cenrifki) | BTK inhibitor | — | 60 mg orally once daily | Pipeline | 6-month confirmed disability progression (CDP) risk reduction: 31% @ 24 months | — |
| Teriflunomide (Aubagio) | Pyrimidine synthesis inhibitor | Multiple sclerosis | 7 mg or 14 mg orally once daily | 2012 | 31.5% @ 108 weeks | $110k |
| Ocrelizumab (Ocrevus) | Anti-CD20 monoclonal antibody | Multiple Sclerosis | Initial dose of 300 mg IV infusion, followed 2 weeks later by a second 300 mg IV infusion. Maintenance dose of 600 mg IV infusion every 6 months. | 2017 | 0.16relapses/year @ 96 weeks | $70k |
| Ofatumumab (Kesimpta) | Anti-CD20 monoclonal antibody | Chronic Lymphocytic Leukemia, Multiple Sclerosis | 20 mg subcutaneously once monthly (following initial loading doses at weeks 0, 1, and 2) | 2020 | 0.11relapses/year @ up to 30 months | $118k |
| Ublituximab (Briumvi) | Anti-CD20 monoclonal antibody | Relapsing forms of multiple sclerosis | 150 mg IV infusion on Day 1, 450 mg on Day 15, then 450 mg every 24 weeks | 2022 | 0.076relapses/year @ 96 weeks | $59k |
| Evobrutinib | BTK inhibitor | — | — | Pipeline | — | — |
| Fenebrutinib | BTK inhibitor | — | Oral, twice daily | Pipeline | 51.1% vs teriflunomide @ 96 weeks | — |
| Remibrutinib (Rhapsido) | BTK inhibitor | chronic spontaneous urticaria | Oral twice daily | Pipeline | — | — |
Cost estimates are list-price approximations and do not reflect rebates, formulary tier, or out-of-pocket costs after benefits. The class-typical lead-pivotal endpoint here is Annualized Relapse Rate (ARR); cells render each drug's actual pivotal endpoint, which may differ. The "Year approved" column shows the FDA approval year for multiple sclerosis specifically — drugs approved for other indications first appear with their this-indication date, or as Pipeline if not yet approved for this indication. Cross-trial comparisons can mislead — head-to-head Phase-3 data (when present) is below.
Tolebrutinib vs Teriflunomide (Aubagio)
The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT06372145) enrolling 2,500 participants, primary completion 2029-04.
Primary-endpoint values for NCT06372145 are not yet posted in the AACT results database.
Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.
Tolebrutinib vs Ocrelizumab (Ocrevus)
No head-to-head Phase-3 trial directly compares Tolebrutinib with Ocrelizumab.
In separate pivotal trials, Tolebrutinib reported 31% 6-month confirmed disability progression (CDP) risk reduction at 24 months (NCT04411641) versus 0.16relapses/year Annualized Relapse Rate (ARR) at 96 weeks for Ocrelizumab (NCT01247324).
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Tolebrutinib vs Ofatumumab (Kesimpta)
No head-to-head Phase-3 trial directly compares Tolebrutinib with Ofatumumab.
In separate pivotal trials, Tolebrutinib reported 31% 6-month confirmed disability progression (CDP) risk reduction at 24 months (NCT04411641) versus 0.11relapses/year Annualized Relapse Rate (ARR) at up to 30 months for Ofatumumab (NCT02792218).
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Tolebrutinib vs Ublituximab (Briumvi)
No head-to-head Phase-3 trial directly compares Tolebrutinib with Ublituximab.
In separate pivotal trials, Tolebrutinib reported 31% 6-month confirmed disability progression (CDP) risk reduction at 24 months (NCT04411641) versus 0.076relapses/year Annualized Relapse Rate (ARR) at 96 weeks for Ublituximab (NCT03277261).
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Tolebrutinib vs Remibrutinib (Rhapsido)
No head-to-head Phase-3 trial directly compares Tolebrutinib with Remibrutinib.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Pipeline alternatives
Several investigational IL-17 / IL-17-related drugs are currently in active Phase 3 development. Fenebrutinib, sponsored by Hoffmann-La Roche, is being evaluated in a lead Phase 3 trial, NCT04586023. Another agent, Remibrutinib, developed by Novartis, also has a lead Phase 3 trial identified as NCT05156281. Evobrutinib is also in Phase 3 development, though its sponsor is currently unknown.
Choosing between Tolebrutinib and its alternatives
Tolebrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, offers a distinct mechanism of action compared to other available therapies. Its pathway of action differs from agents like teriflunomide, which inhibits pyrimidine synthesis, and the anti-CD20 monoclonal antibodies such as ocrelizumab, ofatumumab, and ublituximab. The oral administration of Tolebrutinib may provide a convenient dosing option for some patients, contrasting with the intravenous or subcutaneous schedules required for many other treatments. While specific efficacy data for Tolebrutinib is not presented here, its targeted BTK inhibition could be a consideration for clinicians exploring alternative therapeutic strategies.
Conversely, clinicians may consider agents with a longer established clinical track record and published efficacy data. Teriflunomide (Aubagio) has demonstrated an Annualized Relapse Rate (ARR) reduction of 31.5% at 108 weeks with once-daily oral dosing. Anti-CD20 monoclonal antibodies also offer established efficacy, with ocrelizumab (Ocrevus) reporting an ARR of 0.16 relapses/year at 96 weeks, ofatumumab (Kesimpta) an ARR of 0.11 relapses/year, and ublituximab (Briumvi) an ARR of 0.076 relapses/year. These agents, with their distinct B-cell targeting mechanism, may be preferred for patients where this specific pathway is deemed most appropriate. Remibrutinib, another oral BTK inhibitor, is also in development, though its efficacy data is not yet available.
Ultimately, the choice of therapy is a complex clinical decision that should be made by the prescriber in consultation with the patient, considering individual patient characteristics, disease activity, and treatment goals. This information is not intended as medical advice.
Sources and methodology
Trial data was pulled from the ClinicalTrials.gov registry via the AACT relational mirror maintained by the Clinical Trials Transformation Initiative. AACT data freshness: .
Head-to-head trials cited on this page:
- NCT06372145: Tolebrutinib vs Teriflunomide · A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Cross-trial comparison limitations:drugs without a direct head-to-head trial are compared using each drug's own pivotal trial. These trials enrolled different patient populations at different time points and used different statistical analysis sets. Cross-trial response-rate differences should not be interpreted as proof that one drug is more effective than another.
Related drug pages on Hipa.ai
Not medical advice. This page summarizes publicly-reported clinical trial data for informational purposes. Treatment decisions belong with a qualified prescribing clinician who knows your medical history. Drug approvals, dosing, and safety profiles change over time — always confirm with the current FDA prescribing information.
tolebrutinibtolebrutinib alternativesalternativescomparisonmultiple sclerosisbtk-multiple-sclerosistolebrutinib vs teriflunomidetolebrutinib vs ocrelizumabtolebrutinib vs ofatumumabtolebrutinib vs ublituximabtolebrutinib vs evobrutinib